Gadolinium-DTPA in magnetic resonance imaging of the brain.
This report concerns a clinical trial with Gd-DTPA as an intravenous contrast medium for MRI in patients with neurological disorders. 50 patients (30 female, 20 male) were examined without and with Gd-DTPA and the results of CT scanning and MR scanning without and with Gd-DTPA were compared. All patients tolerated the contrast medium very well. In the various patient groups, Gd-DTPA often added to the information. This was especially true in the tumor group, where better delineation of tumor, blood, and edema was obtained.
Valk
J
J
Department of Diagnostic Radiology, Free University Hospital, Amsterdam, The Netherlands.
De Slegte
R G
RG
Crezee
F C
FC
Hazenberg
G J
GJ
Thjaha
S I
SI
D000328:Adult; D000368:Aged; D001921:Brain / Q000473:pathology*; D001927:Brain Diseases / Q000175:diagnosis*; D001932:Brain Neoplasms / Q000175:diagnosis; D005260:Female; D005682:Gadolinium; D019786:Gadolinium DTPA; D006801:Humans; D008279:Magnetic Resonance Imaging / Q000379:methods*; D008297:Male; D008875:Middle Aged; D009942:Organometallic Compounds; D004369:Pentetic Acid; D014057:Tomography, X-Ray Computed
D009942:Organometallic Compounds; D004369:Pentetic Acid; D005682:Gadolinium; D019786:Gadolinium DTPA